Skip to main navigation Skip to search Skip to main content

A small-molecular inhibitor against Proteus mirabilis urease to treat catheter-associated urinary tract infections

  • Scarlet Milo
  • , Rachel A Heylen
  • , John Glancy
  • , George T Williams
  • , Bethany L Patenall
  • , Hollie J Hathaway
  • , Naing T Thet
  • , Sarah L Allinson
  • , Maisem Laabei
  • , A Toby A Jenkins*
  • *Corresponding author for this work

    Research output: Contribution to journal › Article (Academic Journal) › peer-review

    42 Citations (Scopus)

    Abstract

    Infection and blockage of indwelling urinary catheters is significant owing to its high incidence rate and severe medical consequences. Bacterial enzymes are employed as targets for small molecular intervention in human bacterial infections. Urease is a metalloenzyme known to play a crucial role in the pathogenesis and virulence of catheter-associated Proteus mirabilis infection. Targeting urease as a therapeutic candidate facilitates the disarming of bacterial virulence without affecting bacterial fitness, thereby limiting the selective pressure placed on the invading population and lowering the rate at which it will acquire resistance. We describe the design, synthesis, and in vitro evaluation of the small molecular enzyme inhibitor 2-mercaptoacetamide (2-MA), which can prevent encrustation and blockage of urinary catheters in a physiologically representative in vitro model of the catheterized urinary tract. 2-MA is a structural analogue of urea, showing promising competitive activity against urease. In silico docking experiments demonstrated 2-MA's competitive inhibition, whilst further quantum level modelling suggests two possible binding mechanisms.

    Original languageEnglish
    Article number3726
    Number of pages15
    JournalScientific Reports
    Volume11
    Issue number1
    DOIs
    Publication statusPublished - 12 Feb 2021

    Bibliographical note

    Publisher Copyright:
    © The Author(s) 2021.

    Keywords

    • Amidines/pharmacology
    • HaCaT Cells
    • Humans
    • Molecular Docking Simulation
    • Molecular Targeted Therapy
    • Proteus Infections/drug therapy
    • Proteus mirabilis/enzymology
    • Toxicity Tests
    • Urease/antagonists & inhibitors
    • Urinary Catheterization/adverse effects
    • Urinary Tract Infections/drug therapy

    Fingerprint

    Dive into the research topics of 'A small-molecular inhibitor against Proteus mirabilis urease to treat catheter-associated urinary tract infections'. Together they form a unique fingerprint.

    Cite this